These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 8464593)

  • 21. Clinical evaluation of cefpodoxime proxetil dry syrup in pediatric cutaneous bacterial infection.
    Terui T; Tagami H
    J Chemother; 1995 Nov; 7 Suppl 4():119-21. PubMed ID: 8904129
    [No Abstract]   [Full Text] [Related]  

  • 22. Cefpodoxime proxetil: a third-generation oral cephalosporin. International Congress for Infectious Diseases, Montreal, Canada, 15-19 July 1990.
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():1-101. PubMed ID: 1981370
    [No Abstract]   [Full Text] [Related]  

  • 23. Lack of correlation between in vitro susceptibility data of anaerobes to ceftizoxime and clinical response.
    Wikler MA; Moonsammy GI; Nichols RL
    J Chemother; 1989 Jul; 1(4 Suppl):660-1. PubMed ID: 16312580
    [No Abstract]   [Full Text] [Related]  

  • 24. RWJ-333441 Microcide/RW Johnson.
    Jiraskova N
    Curr Opin Investig Drugs; 2001 Feb; 2(2):209-11. PubMed ID: 11816832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drugs recently released in Belgium. Cefpodoxime proxetil--Fosinopril.
    Harvengt C
    Acta Clin Belg; 1993; 48(4):284-7. PubMed ID: 8212980
    [No Abstract]   [Full Text] [Related]  

  • 26. Disc diffusion-based screening tests for extended-spectrum beta-lactamases in Haemophilus influenzae.
    Tristram SG; Bozdogan B; Appelbaum PC
    J Antimicrob Chemother; 2005 Apr; 55(4):570-3. PubMed ID: 15728142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cefpodoxime, the new oral 3rd generation cephalosporin. Symposium of the 17th International Chemotherapy Congress (ICC). Berlin, 26 June 1991].
    Fortschr Med Suppl; 1991; 114():1-15. PubMed ID: 1682227
    [No Abstract]   [Full Text] [Related]  

  • 28. In vitro evaluation of Ly 163892, a new oral cephalosporin.
    Schäfer V; Knothe H; Sammann A; Heidron F
    J Chemother; 1989 Jul; 1(4 Suppl):123-4. PubMed ID: 16312333
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment of infectious complications affecting the skin and soft tissues with cefpodoxime proxetil].
    Vyhnánek F; Lochmann O
    Epidemiol Mikrobiol Imunol; 1996 May; 45(2):68-70. PubMed ID: 8756403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of cefpodoxime proxetil dry syrup in pediatric patients with various infections.
    Muranaka H; Yokoyama M
    J Chemother; 1995 Nov; 7 Suppl 4():127-30. PubMed ID: 8904132
    [No Abstract]   [Full Text] [Related]  

  • 31. A multi-institutional study on clinical effectiveness of cefpodoxime proxetil dry syrup in childhood infections.
    Imanaka H; Kitahara T; Yoshinaga M; Miyata K
    J Chemother; 1995 Nov; 7 Suppl 4():131-3. PubMed ID: 8904133
    [No Abstract]   [Full Text] [Related]  

  • 32. In vitro study to compare sensitivity of amoxicillin+clavulanic acid and cefpodoxime+clavulanic acid among beta-lactamase positive clinical isolates of gram-positive and gram-negative pathogens.
    Pal RB; Pal P; Jain S; Kulkarni KP
    J Indian Med Assoc; 2008 Aug; 106(8):545-8. PubMed ID: 18975519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of cefixime versus ceftizoxime against Salmonella typhi.
    Rastegar Lari A; Validi N; Ghaffarzadeh K; Shamshiri AR
    Pathol Biol (Paris); 1997 May; 45(5):415-9. PubMed ID: 9296095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FK037, a new parenteral cephalosporin with a broad antibacterial spectrum: synthesis and antibacterial activity.
    Ohki H; Kawabata K; Okuda S; Kamimura T; Sakane K
    J Antibiot (Tokyo); 1993 Feb; 46(2):359-61. PubMed ID: 8468254
    [No Abstract]   [Full Text] [Related]  

  • 36. Water-soluble phosphate prodrugs of pleuromutilin analogues with potent in vivo antibacterial activity against Gram-positive pathogens.
    Fu L; Jiang Z; Cai Z; Liu X; He H; Yang Y
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5407-10. PubMed ID: 19682897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the antimicrobial activity of cefuroxime with other oral antibiotics.
    Wiedemann B; Heisig P
    J Chemother; 1989 Jul; 1(4 Suppl):93-6. PubMed ID: 16312320
    [No Abstract]   [Full Text] [Related]  

  • 38. The comparative plasma pharmacokinetics of intravenous cefpodoxime sodium and oral cefpodoxime proxetil in beagle dogs.
    Brown SA; Boucher JF; Hubbard VL; Prough MJ; Flook TF
    J Vet Pharmacol Ther; 2007 Aug; 30(4):320-6. PubMed ID: 17610405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of the third generation oral cephalosporin cefpodoxime in biological fluids by high-speed high-performance liquid chromatography.
    Molina F; Jehl F; Gallion C; Penner F; Monteil H
    J Chromatogr; 1991 Jan; 563(1):205-10. PubMed ID: 2061390
    [No Abstract]   [Full Text] [Related]  

  • 40. Bioavailability of cefpodoxime proxetil with co-administered acetylcysteine.
    Kees F; Wellenhofer M; Bröhl K; Grobecker H
    Arzneimittelforschung; 1996 Apr; 46(4):435-8. PubMed ID: 8740095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.